Blog › ICP guides

Regulatory affairs consultant on retainer: tracking FDA advisory hours and demonstrating ongoing regulatory strategy value

July 14, 2026 · ~13 min read

The most common way clients evaluate a regulatory affairs consulting retainer is by pointing to completed submissions: the 510(k) that cleared, the Pre-Sub meeting that happened, the IDE that was approved. What they do not see is the continuous advisory between those visible milestones — the regulatory intelligence scan that flagged a new FDA draft guidance document affecting the client’s predetermined change control plan before the next product modification was designed, the post-market surveillance review that identified a complaint pattern requiring MDR evaluation before the 30-day reporting window closed, the labeling review that prevented the client from publishing an Instructions for Use revision that would have claimed a new intended use not within the cleared indications.

Regulatory affairs consultants and fractional VP-Regulatory Affairs advisors on monthly retainer do most of their highest-impact work in the continuous intelligence monitoring, post-market surveillance oversight, labeling compliance review, and quality system advisory that keeps the client’s products in compliance and the regulatory pathway clear between formal submissions. Medical device, pharmaceutical, and biotech companies that stay in compliance do not do so by filing one submission and waiting for the next development milestone. They maintain that compliance through continuous regulatory advisory that most clients cannot see on a monthly invoice.

The advisory month where no applicable FDA guidance went unreviewed, no post-market complaint triggered an unreported adverse event, no labeling change was made that would have constituted an uncleared new indication, and no quality system gap was left unaddressed is the month where the regulatory affairs retainer delivered exactly what it was retained to deliver. That continuous advisory function is also the most systematically invisible output on a monthly invoice that says “regulatory affairs advisory, 18 hours.”

This guide covers what regulatory affairs consulting retainer work actually consists of, what categories of ongoing advisory are most commonly underlogged, how to structure and communicate hours so clients understand the continuous work between submissions, and the contract clauses that define scope in regulatory affairs retainer engagements.

Regulatory affairs consulting versus healthcare consulting: defining the boundary

Regulatory affairs consulting and healthcare consulting are both deeply regulatory domains but address fundamentally different regulated entities, different applicable regulations, and different types of clients. Understanding the distinction is important for scoping any regulatory advisory engagement.

A healthcare consultant on retainer advises healthcare providers — hospitals, health systems, physician practices, ambulatory surgery centers, post-acute care facilities — on the regulatory environment governing how healthcare services are delivered and reimbursed. The applicable regulations are CMS Conditions of Participation, CMS reimbursement methodologies, HIPAA privacy and security requirements, Stark Law and Anti-Kickback Statute, Joint Commission accreditation standards, and state licensure requirements. The healthcare consultant’s client is a service provider navigating the regulations that govern their clinical operations and revenue cycle.

A regulatory affairs consultant on retainer advises manufacturers of FDA-regulated products — medical devices, in vitro diagnostics, pharmaceuticals, biologics, dietary supplements, food products, cosmetics, or combination products — on the regulatory strategy required to achieve and maintain product market authorization. The applicable regulations are FDA product-specific regulations: 21 CFR Parts 800–898 for medical devices; 21 CFR Parts 200–499 for pharmaceutical products; 21 CFR Part 820 Quality System Regulation; FDA guidance documents for specific product categories and submission types. The RA consultant’s client is a manufacturer navigating the regulations that govern whether their product may be legally marketed and how.

The distinction matters for retainer scoping: a manufacturer of medical devices needs regulatory affairs advisory; a hospital purchasing those same devices needs healthcare consultant advisory. These are different professional disciplines with different expertise, different agency relationships, and different deliverables. Both are regulatory; neither substitutes for the other.

What ongoing regulatory affairs advisory retainer work actually consists of

Regulatory intelligence monitoring

FDA’s regulatory output is continuous: guidance documents are issued, draft guidance is published for comment, warning letters are posted, 483 inspection observations reveal agency enforcement priorities, final rules are published in the Federal Register, and device recall notices indicate product safety concerns. A manufacturer whose regulatory strategy was developed based on the guidance landscape from three years ago may be planning submissions, labeling, or quality system practices that no longer reflect current FDA expectations.

Regulatory intelligence monitoring in a retainer context means: systematically reviewing FDA guidance documents, draft guidances, warning letters, Federal Register notices, and relevant conference presentations for developments applicable to the client’s product categories, submission types, and quality system requirements; assessing whether new guidance changes the optimal regulatory pathway for planned submissions; advising on whether draft guidance comments would benefit the client’s product category; and flagging enforcement trends visible in warning letters that indicate evolving agency priorities the client should address before an inspection. A monthly regulatory intelligence scan that reviews applicable FDA outputs and finds nothing requiring immediate action is a complete monitoring cycle — not an absence of regulatory work.

The FDA guidance document that redefines the substantial equivalence standard for a product category changes every in-progress 510(k) for that category. The company whose regulatory advisor identified the draft guidance, monitored the comment process, and adjusted the submission strategy before the guidance finalized avoided the submission failure that the company with no regulatory monitoring encountered. That prevention has no visible deliverable in the month it happened.

Post-market surveillance and adverse event advisory

Device manufacturers are required under 21 CFR Part 803 to report device-related deaths, serious injuries, and malfunctions that could cause death or serious injury within defined reporting windows. Drug manufacturers have analogous requirements under 21 CFR Part 314.81 and 21 CFR Part 600.80. Meeting those reporting obligations requires a trained reviewer who can distinguish reportable from non-reportable events in real time and document the determination before the reporting window expires.

Post-market surveillance advisory in a retainer context means: reviewing complaint and adverse event data at a defined cadence; evaluating each event against the applicable reportability criteria; drafting MDR or MedWatch reports for reportable events; advising on CAPA when post-market data identifies safety signals that require design or process correction; monitoring for complaint trends that indicate emerging safety issues; advising on post-market clinical follow-up obligations for devices with notified body CE marks or ongoing IDE studies; and documenting the surveillance review and reportability determinations for each period. The quarterly post-market surveillance review that evaluates 47 complaints and determines 44 are non-reportable and 3 require MDR evaluation is surveillance advisory regardless of how many reports were ultimately submitted.

Labeling compliance review

Product labeling for FDA-regulated products is not a marketing function. The claims made on device labels and in device promotional materials must be consistent with the cleared or approved indications for use; labeling that adds a new intended use beyond what was cleared constitutes introducing an adulterated or misbranded device under the FD&C Act. The pharmaceutical labeling requirements under 21 CFR Part 201 and the advertising requirements under 21 CFR Part 202 similarly constrain what claims can be made and how.

Labeling compliance review in a retainer context means: reviewing proposed label revisions, Instructions for Use updates, promotional materials, website product pages, and trade show claims against the cleared or approved indications for use; identifying labeling changes that would constitute new use claims requiring a new submission; advising on how to describe product capabilities accurately within the cleared indications; reviewing 510(k) Special Access (SaMD) change requests to assess whether the planned software update triggers a new clearance obligation; and advising on the regulatory classification of changes under 21 CFR Part 806 (device correction and removal) when a labeling error requires a field correction. A labeling review that evaluates a proposed IFU revision and confirms the language is consistent with cleared indications is a complete compliance review.

Quality system advisory

FDA’s Quality System Regulation (21 CFR Part 820 for devices; cGMP requirements for pharmaceutical manufacturers) is not a one-time implementation. It is a continuously operated system that generates design history file documentation, CAPA records, supplier qualification records, and production and process control records throughout the product lifecycle. The manufacturer whose quality system was implemented correctly at 510(k) clearance but whose design controls are not adequately capturing post-market design changes — or whose CAPA process is closing corrective actions without adequate effectiveness verification — is accumulating compliance risk that will be visible at the next FDA inspection.

Quality system advisory in a retainer context means: advising on design control documentation for new product development and post-market design changes, including when a change constitutes a significant device modification requiring a new 510(k); reviewing CAPA documentation for adequacy of root cause analysis and effectiveness verification; advising on supplier qualification requirements under 21 CFR 820.50 and the documentation needed for critical component suppliers; reviewing complaint and MDR procedures; advising on FDA inspection readiness and the documentation package the FDA investigator is likely to request; and advising on whether a 483 observation from a competitor’s inspection warning letter indicates a compliance priority the client should self-assess. These advisory conversations often have no associated NCR or CAPA — they shape the client’s quality system posture before the compliance gap materializes.

Regulatory strategy and pathway advisory

The regulatory pathway decision for a new medical device — 510(k) versus De Novo versus PMA; with or without a pre-submission meeting; with IDE or without; with MDUFA performance goal timing or expedited review designation — determines the submission timeline, the evidence package required, and the post-market requirements the manufacturer will carry for the device’s commercial life. Getting that pathway decision wrong at product development initiation is the most expensive regulatory error a device company can make, because it is discovered during or after a submission that required 12–18 months of development work.

Regulatory strategy in a retainer context means: advising on the regulatory pathway for new products and product modifications; advising on the predicate selection strategy for 510(k)s and the substantial equivalence argument structure; planning the pre-submission meeting strategy to align with FDA on key technical and regulatory questions before the formal submission; advising on the evidence generation requirements — bench testing, biocompatibility, software validation, clinical evidence — that FDA will expect for the planned pathway; and reviewing the product roadmap periodically to identify how planned future modifications may affect the existing submission portfolio. A regulatory strategy review session that assesses the product roadmap and confirms the planned submission sequence remains appropriate is a complete strategy review.

FDA interaction support and Q-submission management

FDA’s Q-Submission (pre-submission meeting) program allows manufacturers to seek FDA feedback on questions about regulatory strategy, proposed study designs, and testing approaches before a formal submission. Q-Submissions are among the most high-value regulatory interactions a manufacturer can have — FDA feedback on whether the proposed 510(k) predicate is acceptable, whether the bench testing protocol is adequate, or whether the clinical study design meets the performance data requirements can prevent months of submission deficiency review.

Q-Submission management in a retainer context means: identifying the regulatory questions where FDA feedback would materially reduce submission risk; drafting the Q-Submission meeting request and question list; preparing the technical package that supports the questions; preparing the client team for the FDA meeting; reviewing FDA feedback and advising on the strategy implications; and tracking the Q-Submission response to inform the formal submission development. Q-Submission preparation frequently consumes 15–25 advisory hours before the meeting request is even filed — hours that appear on retainer work logs before any formal submission activity begins.

Three modes of regulatory affairs advisory retainer intensity

Regulatory affairs advisory retainers operate at different intensity levels depending on the client’s submission pipeline activity and post-market surveillance volume.

Steady-state advisory (15–30 hours/month): The baseline mode for a client with cleared products, no active submissions in development, and a routine post-market surveillance volume. Core work: regulatory intelligence monitoring, post-market surveillance review and MDR determination, labeling compliance review for marketing and sales materials, quality system advisory, and regulatory strategy maintenance for the product roadmap. This mode is the most systematically underlogged because no submission is in active development.

Active FDA submission (40–80 hours/month, compressed): When the client is preparing a 510(k), PMA, NDA, or BLA, advisory hours increase substantially to cover submission writing advisory, technical file review, predicate strategy refinement, FDA correspondence management, and deficiency response development. These periods are submission-visible and rarely underlogged.

Regulatory response or FDA inspection preparation (50–100 hours, compressed): When the client has received a Warning Letter, a 483 inspection observation, or a Complete Response Letter requiring a major submission revision, or when an FDA inspection is imminent, advisory hours are high and time-compressed. These periods require explicit scope conversations because they can consume the entire retainer budget in a single month.

Regulatory affairs advisory retainer pricing

Regulatory affairs consulting retainer rates reflect the advisor’s seniority, the product category and regulatory complexity involved, and whether the retainer includes submission writing in addition to strategy advisory. Market rates for independent regulatory affairs consultants on monthly retainer fall into three general brackets:

$100–$175/hour for RA professionals with 5–10 years of experience in 510(k) submissions, quality system implementation, or pharmaceutical regulatory operations, capable of managing routine post-market surveillance, reviewing labeling for compliance, and advising on standard 510(k) pathways. Monthly retainers at this level typically run $2,000–$5,500/month for steady-state advisory (15–30 hours).

$150–$275/hour for senior regulatory affairs consultants with deep expertise in specific product categories (Class III devices, 510(k) De Novo, combination products, pharmaceutical NDA/505(b)(2) submissions), significant regulatory strategy experience (Pre-Sub meetings, clinical protocol alignment, MDUFA performance goal management), or quality system remediation experience. Monthly retainers at this level typically run $4,000–$8,500/month for steady-state advisory.

$200–$400/hour for principal-level advisors with FDA-negotiation experience, Warning Letter response leadership, PMA or BLA regulatory strategy expertise, fractional VP-Regulatory Affairs background, or deep specialization in high-risk product categories (implantable devices, biologics, novel drug-device combination products). Monthly retainers at this level typically run $5,000–$12,000/month.

What regulatory affairs advisory retainer work is most commonly underlogged

The advisory work most systematically absent from regulatory affairs retainer work logs is the continuous surveillance and intelligence work that produces determinations of “no reporting obligation” or “no pathway change required” rather than a completed submission.

1. Regulatory intelligence scans where no applicable guidance was identified. Reviewing FDA guidance documents, warning letters, and regulatory publications for a month and confirming none requires a change to the client’s regulatory strategy is a complete monitoring cycle. The guidance that did not apply still required professional review to determine it did not apply. Log every monitoring cycle with the regulatory outputs reviewed and the applicability determination.

2. Post-market surveillance reviews where no MDR was triggered. Reviewing complaint and adverse event data and determining that all events are below the MDR reportability threshold is a regulatory determination that required professional judgment under 21 CFR Part 803. The finding of “no reports due” is the most common outcome of a correctly operating post-market surveillance system — and it requires the same review cycle as the finding that triggers a report. Log every surveillance review with the number of complaints reviewed, the reportability assessments performed, and the period determination.

3. Labeling reviews for changes that were not made. Reviewing a proposed IFU revision or marketing claim and advising against publishing because it would exceed cleared indications or constitute an unapproved new use requires the same regulatory analysis as approving a change. The label that was not published because a regulatory professional reviewed it prevented a regulatory compliance violation. Log every labeling review with the material reviewed, the regulatory assessment performed, and the recommendation — including recommendations against proceeding.

4. Quality system advisory with no associated NCR or CAPA. Advising a product development team on how their planned design change should be documented in the design history file — without any active nonconformance triggering the conversation — is quality system advisory that shapes the client’s compliance posture before any gap appears. These conversations frequently go unlogged because they are informal. Every quality system advisory conversation should have a work log entry with the design element, quality system requirement, and advisory recommendation.

5. Q-Submission or pre-submission meeting preparation before the meeting request is filed. Developing the regulatory questions, framing the technical package, and preparing the client team for an FDA pre-submission meeting is regulatory strategy work that consumes 10–25 hours before any formal FDA interaction. This preparation is invisible in work logs because the formal submission event has not yet occurred. Log pre-submission preparation as a distinct category with the submission being planned and the questions being developed.

6. Regulatory strategy reviews where no pathway changes were recommended. Periodically reviewing the product roadmap against the current regulatory strategy and confirming the planned submission sequence remains appropriate given the competitive device landscape and current FDA expectations is a complete strategy review. The development program that proceeded on the correct regulatory pathway because the strategy was periodically validated is not the same as the program that proceeded by assumption. Log strategy reviews with the products assessed and the pathway validation finding.

Critical clauses in regulatory affairs consulting retainer agreements

Regulatory monitoring scope. Specify which product categories, device classifications, and regulatory programs are within the ongoing intelligence monitoring scope. A regulatory affairs advisor retained for Class II medical device regulatory strategy who is asked to advise on dietary supplement regulatory compliance or pharmaceutical advertising review is operating outside the scoped expertise. Define the product category boundary before cross-category requests arrive.

Advisory versus regulatory agent boundary. Define whether the consultant advises on regulatory strategy or also signs submissions as FDA regulatory contact, represents the manufacturer in formal FDA correspondence, or is identified as the regulatory affairs representative in 510(k) submissions. The regulatory agent role carries different liability implications than advisory. Define which role the consultant is filling before FDA contact is initiated.

Post-market surveillance scope. Define which product lines, adverse event data streams, and complaint sources are within the ongoing surveillance review scope. A multi-product manufacturer with 12 cleared devices has a substantially different surveillance scope than a single-product startup. Define the surveillance scope and what reporting cadence the client will maintain for complaint intake and MDR determination.

Submission development scope. Define whether the retainer includes FDA submission writing, technical file compilation, and formal submission management, or only advisory on regulatory strategy, pathway decisions, and submission approach review. Submission writing is substantially more time-intensive than strategy advisory and is frequently scoped as a separate project engagement triggered alongside the steady-state retainer.

Quality system advisory scope. Define which elements of the quality management system are within the ongoing advisory scope. Design controls advisory is a different scope than CAPA advisory, supplier qualification advisory, or production and process controls review. Define which quality system domains are within the retainer before the scope expands in response to an audit finding or 483 observation.

Making ongoing regulatory advisory visible

The fundamental challenge of a regulatory affairs consulting retainer is that the continuous intelligence monitoring, post-market surveillance review, labeling compliance assessment, and quality system advisory that keeps the client’s products in compliance is invisible at the time it happens and invisible on a monthly invoice that says “regulatory affairs advisory, 20 hours.” The FDA guidance document that did not change the regulatory strategy because it was identified, evaluated, and assessed as non-applicable, the MDR that was not filed because the complaint was reviewed and determined non-reportable, the IFU revision that was not published because a professional identified the new-use claim before it reached FDA — none of that has a visible signature in the business without a work log.

A retainer hours URL with a running regulatory advisory work log changes that dynamic. When a client reviews the dashboard mid-month and sees a regulatory intelligence entry for the April FDA guidance review cycle with specific documents assessed and the applicability determination, a post-market surveillance entry for Q2 complaint review with individual event assessments and the period MDR determination, a labeling review entry for the new product page draft with the claims assessed and the recommendation, and a quality system advisory entry for the design change discussion with the DHF documentation approach recommended, the month’s advisory is legible as a documented professional regulatory service before the invoice arrives.

For manufacturers of FDA-regulated products — where a single unreported MDR, a single out-of-indication labeling claim, or a single quality system gap discovered at inspection can produce an FDA Warning Letter, consent decree, or mandatory product recall — the accumulated regulatory advisory work log over twelve months becomes the primary record of what the continuous regulatory oversight function produced. A client reviewing that log sees not just hours but specific professional regulatory work: guidance monitored and strategy confirmed, adverse events assessed and reporting obligations determined, labeling reviewed and compliance maintained, quality system gaps addressed before inspection, regulatory pathway validated and submission sequence confirmed. That record is the evidence that the retainer produced real regulatory value across every month of the engagement, including the months when no submission was filed.

Regulatory affairs consultants who make the continuous monitoring and compliance advisory work visible through systematic work logging and a shared retainer hours dashboard convert the retainer from a submission-event service into a documented regulatory function with traceable, professional output. The client who has watched the regulatory advisory log build throughout the year — intelligence monitored, surveillance reviewed, labeling assessed, quality system maintained, regulatory strategy validated — arrives at the renewal conversation able to point to the specific advisory work that kept the products in compliance and the regulatory pathway clear. The regulatory compliance that held every month does not speak for itself. The work log does.

Frequently asked questions

What does a regulatory affairs consultant on retainer typically do?

A regulatory affairs consultant or fractional VP of Regulatory Affairs on monthly retainer monitors FDA regulatory intelligence for developments applicable to the client’s product categories, reviews adverse event and complaint data for MDR reporting obligations, evaluates labeling and promotional materials for compliance with cleared or approved indications, advises on quality system documentation and inspection readiness, and maintains the regulatory strategy for the client’s product portfolio and pipeline. The retainer covers the continuous regulatory advisory function; the most valuable deliverable is compliant products and a clear regulatory pathway — which is the least visible output between formal submissions.

How is a regulatory affairs consultant different from a healthcare consultant?

A healthcare consultant advises healthcare providers — hospitals, physician practices, health systems — on CMS reimbursement, clinical operations, EHR implementation, and provider-side regulatory compliance (Stark Law, HIPAA, Joint Commission). A regulatory affairs consultant advises manufacturers of FDA-regulated products — medical devices, pharmaceuticals, biologics, dietary supplements — on product regulatory strategy, FDA submission pathways, post-market surveillance obligations, and quality system compliance. The regulated entity, applicable regulations, and required expertise are all distinct.

What regulatory affairs advisory retainer work is most commonly underlogged?

The most systematically underlogged categories are: regulatory intelligence scans where no applicable guidance was identified; post-market surveillance reviews where no MDR reporting obligation was triggered; labeling reviews for changes that were not made; quality system advisory conversations with no associated NCR or CAPA; Q-Submission preparation before the meeting request is filed; and regulatory strategy reviews where no pathway changes were recommended. All represent the regulatory advisory function working correctly, and all produce outcomes that are invisible without a work log.

What should a regulatory affairs consulting retainer agreement include?

The agreement should define the regulatory monitoring scope, the product scope, the advisory versus regulatory agent boundary, the post-market surveillance scope and reporting cadence, the quality system advisory scope, and the submission development scope. Hours visibility access allows the client to follow the ongoing regulatory advisory work between formal FDA submissions and understand what the monthly retainer is producing.

How should regulatory affairs consulting retainer hours be logged?

Log entries should capture the advisory function (regulatory intelligence, post-market surveillance, labeling compliance, quality system advisory, regulatory strategy, FDA interaction), the specific product, regulation, or agency program involved, the activity performed, and the finding or regulatory determination — including determinations of no applicable guidance, no reportable event, and no labeling change required. A work log at that level converts “regulatory affairs advisory, 20 hours” into a traceable record of the guidance reviewed, adverse events assessed, labeling evaluated, quality system advised, and regulatory strategy maintained across the month. That record is what makes the continuous regulatory oversight visible to the client between FDA submissions.